Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Trauner

Showing results (591-600 of 777) with videos related to

Pageof 78
Sort By:
Iscience|December 24, 2025
Fiber enrichment is not superior to dietary monitoring in MASLD: A dual-center, double-blind, placebo-controlled trialAnnette Brandt, Timur Yergaliyev, Emina Halibasic, et al.
European Radiology Experimental|August 12, 2025
MRI-derived quantification of hepatic vessel-to-volume ratios in chronic liver disease using a deep learning approachAlexander Herold, Daniel Sobotka, Lucian Beer, et al.
AIDS (London, England)|July 10, 2013
The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patientsMattias Mandorfer, Karin Neukam, Thomas Reiberger, et al.
Journal of Hepatology|February 25, 2014
Characterization of animal models for primary sclerosing cholangitis (PSC)Peter Fickert, Marion J Pollheimer, Ulrich Beuers, et al.
Journal of Hepatology|March 1, 2017
NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated miceElisabeth Krones, Kathrin Eller, Marion J Pollheimer, et al.
European Radiology|September 27, 2022
Imaging features facilitate diagnosis of porto-sinusoidal vascular disorderKatharina Lampichler, Georg Semmler, Katharina Wöran, et al.
BMC Gastroenterology|March 16, 2023
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitisMichael Trauner, Chuhan Chung, Kate Sterling, et al.
RMD Open|November 14, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature researchAndreas Kerschbaumer, Josef S Smolen, Peter Nash, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2022
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSCMichael Trauner, Christopher L Bowlus, Aliya Gulamhusein, et al.
Plos One|January 10, 2018
Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experienceTheresa Bucsics, Maria Schoder, Magdalena Diermayr, et al.
Pageof 78

Showing results (591-600 of 777) with videos related to

Sort By:
Pageof 78
Iscience|December 24, 2025
Fiber enrichment is not superior to dietary monitoring in MASLD: A dual-center, double-blind, placebo-controlled trialAnnette Brandt, Timur Yergaliyev, Emina Halibasic, et al.
European Radiology Experimental|August 12, 2025
MRI-derived quantification of hepatic vessel-to-volume ratios in chronic liver disease using a deep learning approachAlexander Herold, Daniel Sobotka, Lucian Beer, et al.
AIDS (London, England)|July 10, 2013
The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patientsMattias Mandorfer, Karin Neukam, Thomas Reiberger, et al.
Journal of Hepatology|February 25, 2014
Characterization of animal models for primary sclerosing cholangitis (PSC)Peter Fickert, Marion J Pollheimer, Ulrich Beuers, et al.
Journal of Hepatology|March 1, 2017
NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated miceElisabeth Krones, Kathrin Eller, Marion J Pollheimer, et al.
European Radiology|September 27, 2022
Imaging features facilitate diagnosis of porto-sinusoidal vascular disorderKatharina Lampichler, Georg Semmler, Katharina Wöran, et al.
BMC Gastroenterology|March 16, 2023
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitisMichael Trauner, Chuhan Chung, Kate Sterling, et al.
RMD Open|November 14, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature researchAndreas Kerschbaumer, Josef S Smolen, Peter Nash, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2022
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSCMichael Trauner, Christopher L Bowlus, Aliya Gulamhusein, et al.
Plos One|January 10, 2018
Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experienceTheresa Bucsics, Maria Schoder, Magdalena Diermayr, et al.
Pageof 78